Specify a stock or a cryptocurrency in the search bar to get a summary
Genoway
ALGENgenOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was incorporated in 1999 and is based in Lyon, France. Address: Technopark 2, Lyon, France, 69007
Analytics
WallStreet Target Price
6.21 EURP/E ratio
17.2381Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALGEN
Dividend Analytics ALGEN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALGEN
Stock Valuation ALGEN
Financials ALGEN
Results | 2019 | Dynamics |